IN THE NEWS
Research Explained in 70 Seconds – UMB on Instagram
Imagine being able to carry artificial blood to a wounded soldier in a remote area to save their life. That’s one of the potential benefits of a $46.4 million study to develop and test artificial blood being led by #UMSOM Professor Allan Doctor. @darpa is administering the project. Dozens of universities and biotech companies are also collaborating.
David J. Ramsay Entrepreneur of the Year Video Presentation
The University of Maryland, Baltimore (UMB) produced this video showcasing the work of KaloCyte Co-Founder and Chief Scientific Officer, Allan Doctor MD; recipient of the 2022
Erythromer, a nanoscale bio-synthetic artificial red cell
VJHemOnc Video Journal of Hematological Oncology Published on Dec 16, 2016 Press brief by Allan Doctor, MD of Washington University School of Medicine, St. Louis, MO, on erythromer (EM), a nanoscale bio-synthetic artificial red cell: proof of concept and In vivo...
Video: Artificial blood cells clear first phase of animal testing
SAN DIEGO | An artificial red blood cell has come close to emulating the key functions of natural cells and does not appear to be associated with the side effects such as vasospasm and poor response to changes in blood pH that hampered the development of previous...
CONTACT US
KaloCyte, Inc.
4 N. Martin Luther King Jr. Blvd
Suite 300
Baltimore, MD 21201
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.